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Abstract: Chronic heart failure (CHF) is a pathological state with high morbidity and mortality and the full understanding 
of its genesis remain to be elucidated. In this syndrome, a cascade of neurohormonal and hemodynamic mechanisms, as 
well as inflammatory mediators, are activated to improve the impaired cardiac function. Clinical and experimental 
observations have shown that CHF is associated with a generalized disturbance in endothelium-dependent vasodilation, 
which may contribute to the progression of ventricular and vascular remodelling in this syndrome. There is also 
accumulating evidence that disturbances in nitric oxide (NO) availability is involved in the development of heart failure at 
the systemic and cardiac levels. NO is a ubiquitous signalling molecule which causes potent vasodilation, inhibits platelet 
activation and regulates the contractile properties of cardiac myocytes. It is generated from the amino acid L-arginine via 
constitutive and inducible isoforms of the enzyme NO synthase (NOS). There is evidence that exercise, a 
nonpharmacological tool, improves symptoms, fitness (VO2peak), quality of life and NO bioavailability in CHF population. 
This review examines different aspects of the L-arginine-NO pathway and inflammation in the physiopathology of CHF 
and highlights the important beneficial effects of exercise in this disease.  
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1. INTRODUCTION  
  Chronic heart failure (CHF) is a clinical syndrome 
caused by an abnormality of the heart and diagnosed by a 
characteristic patterns of haemodynamic, renal and hormonal 
responses [1]. The prevalence of this disease is high 
throughout the world, with 50% of patients dying within four 
years and of 50% of patients with severe heart failure dying 
within one year [2]. 
  Endothelium-dependent dilation of resistance vessels in 
response to acetylcholine is impaired in heart failure and 
related to the clinical severity of the disease [3, 4]. 
Endothelial dysfunction seems to contribute to the high 
vascular resistance in the systemic and pulmonary vascular 
beds of patients with chronic heart failure [3-5]. 
Accumulating evidence suggests that endothelial dysfunction 
may result from a decreased release of nitric oxide (NO) or 
an enhanced inactivation of this bioactive mediator [6]. 
  In mammalian cells, NO is formed from the terminal 
guanidino nitrogen atom of L-arginine by a family of NOS  
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enzymes with characteristics of cytochrome P-450 reductase 
[7-9]. The principal mechanism of action of NO is to interact 
with heme moiety of guanylyl cyclase, increasing the 
production of intracellular cyclic guanosine monophosphate 
(cGMP) [9, 10]. Membrane transport of the precursor L-
arginine is essential for physiological NO production and 
alterations in transport may in part help explain several of 
the pathological changes observed in CHF [6].  
  Increasing evidence has demonstrated that habitual 
physical activity can reduce the risk of cardiovascular 
disease [11]. Indeed, a direct correlation of the amount of 
exercise performed and a reduction in mortality due to 
cardiovascular disease has been reported in middle-aged and 
elderly populations [12].  
  This review aims to provide an overview of clinical and 
experimental data on the role of L-arginine-nitric oxide 
pathway and inflammation in the pathophysiology of CHF 
and the potential beneficial effects of exercise in this disease. 
2. PATHOPHYSIOLOGY OF CHRONIC HEART 
FAILURE 
  CHF is a common and complex clinical syndrome whose 
incidence and prevalence is increasing world-wide [13]. 
CHF results from structural or functional cardiac disorders, 
leading to an impaired ability of the ventricle to fill with or 56    The Open Biochemistry Journal, 2009, Volume 3  Mendes-Ribeiro et al. 
eject blood. The cardinal manifestations of CHF are dyspnea 
and fatigue, which may limit exercise tolerance, and fluid 
retention, which may lead to pulmonary congestion and 
peripheral edema [1]. Both abnormalities can impair the 
functional capacity and quality of life of affected individuals, 
but they do not necessarily dominate the clinical picture at 
the same time. Some patients have exercise intolerance but 
little evidence of fluid retention, whereas others complain 
primarily of edema and report few symptoms of dyspnea or 
fatigue [2, 14]. 
  Abnormal left ventricular systolic function from any 
cause appears to stimulate compensatory mechanisms to 
maintain cardiac output, systemic blood pressure and 
perfusion to vital organs. Most important among these are: 
(1) the Frank-Starling mechanism (i.e. the ventricle responds 
to an increased preload by enhancing its contraction; (2) 
ventricular hypertrophy with or without chamber dilation; 
and (3) neurohormonal activation [13-15].  
  Many neurohormonal systems are activated during 
chronic heart failure, such as the renin-angiotensin-
aldosterone system, sympathetic nervous system, endothelin 
and vasopressin, which lead to vasoconstriction and water 
and sodium retention [13, 15, 16]. Neuroendocrine systems 
are interactive and integrated with the brain, kidneys, heart 
and periphery, playing a role in the onset and progression of 
heart failure. Despite presumed initial circulatory 
homeostasis, prolonged neurohormonal activation may 
become highly maladaptive, contributing not only to 
increased afterload and reduced cardiac output but also 
causing necrosis and death of myocardial cells [13, 15, 16].  
  The kidney plays a central role in salt and water retention 
in heart failure. A significant reduction in glomerular 
filtration rate accompanies impaired cardiac output and is 
caused by reduced arterial pressure and by constriction of the 
preglomerular arterioles in response to increased sympathetic 
activity and angiotensin II production [13, 15, 17]. This 
reduction in the glomerular filtration rate reduces sodium 
delivery to the nephron and, associated with direct actions of 
angiotensin II on tubular sodium reabsorption, may cause 
sodium and water retention [17, 18]. The kidney synthesises 
rennin, protease kallikrein and prostaglandins, which are 
increased during chronic heart failure [19, 20]. 
  Whereas neurohormonal factors have been extensively 
studied, the impact of local factors regulating peripheral 
vasomotor tone and tissue perfusion in chronic heart failure 
has been poorly defined. Clinical and experimental 
observations have demonstrated that chronic heart failure is 
associated with a generalised impairment of endothelium-
dependent vasodilation, which may contribute to the 
progression of ventricular and vascular remodelling in this 
syndrome (Mendes Ribeiro et al. 2001). 
3. L-ARGININE – NITRIC OXIDE PATHWAY 
  In 1980, Furchgott et al. (1980) first reported that 
endothelial cells release an endothelium-derived relaxing 
factor (EDRF). In 1987, this molecule was identified as 
being NO [21, 22], a labile gas that can diffuse readily across 
membranes and with a half-life ranging from 2 to 30 s. NO 
can be reduced by the presence of molecular oxygen (O2), 
superoxide anions (O2
-) and heme proteins [23-25]. In 
mammalian cells, NO is synthesized from the terminal 
guanidino nitrogen atoms of L-arginine, a cationic amino 
acid, by NO synthases (NOS) (Fig. 1). This reaction involves 
two monooxygenation steps requiring O2 and NADPH: an 
initial hydroxylation of L-arginine to generate N-hydroxy-L-
arginine, followed by oxidation which leads to the formation 
of NO and L-citrulline [26, 27].  
  To date, three different isoforms of NOS have been 
identified: type I or neuronal (nNOS), type II or inducible 
(iNOS) and type III or endothelial (eNOS) [9, 26]. The 
isoforms nNOS and eNOS are constitutive and their 
activities are regulated by intracellular free calcium and the 
calcium-binding protein calmodulin, whereas the iNOS is 
calcium independent. Despite the well established role of the 
three NOS isoforms, recent evidence support the idea of NO 
production via the mitochondrial membrane in different cell 
types such as liver, kidney and cardiac cells [28-31]. This 
isoform is known as mitochondrial NOS (mtNOS) and it is 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). L-Arginine Nitric Oxide Pathway. GC: guanylyl cyclase; cGMP: cyclic guanosine monophosphate; NO: Nitric oxide; NOS: Nitric 
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still unclear if mtNOS is a new isoform of NOS or a splicing 
of nNOS [30, 32, 33]. 
  Approximately 10 nM of NO is needed to activate 
guanylyl cyclase (GC)-coupled receptors leading to cGMP 
accumulation in vascular smooth muscle cells [34, 35]. 
Studies  in vivo suggested that GC will display a dual 
regulation by NO: long-lasting tonic activity due to 
persistent occupation by NO of the heme binding site and 
phasic activity due to engagement of another unidentified 
site [34]. The cGMP influences a number of vascular cell 
types and regulates vasomotor tone, endothelial permeability, 
cell growth and differentiation, as well as platelet and blood 
cell interactions [36]. Moreover, cGMP increases the 
expression of methylarginine dimethylamino-hydrolase 
(DDAH), an enzyme that metabolizes asymmetric dimethyl- 
arginine, N(G)-dimethyl-L-arginine (ADMA) and N(G)-
monomethyl-L-arginine (L-NMMA), which are competitive 
endogenous inhibitors of NOS. It is possible that this effect 
serves to maintain NO levels in the endothelial environment 
[37]. 
  L-arginine is considered a semi-essential amino acid in 
most adult mammals, but under certain conditions where the 
synthesis of L-arginine is decreased and/or its catabolism is 
increased, L-arginine becomes an essential amino acid [38]. 
In humans, the kidney and dietary intake are responsible for 
maintaining normal plasma levels of this amino acid, which 
range from 80 to 100 μM in healthy patients [39, 40]. 
  Membrane transport of L-arginine in mammalian cells is 
predominantly mediated via four transport systems: y
+, y
+L, 
B
o,+ and b
o,+, with different kinetic patterns [41, 42]. Several 
studies have demonstrated that L-arginine transport is rate 
limiting for generating NO by endothelial cells activated 
macrophages, platelets, endothelium and brain astrocytes, 
despite the fact that the intracellular concentration of L-
arginine remains well above Km values for NOS [43-47]. 
This special feature is known as the “L-arginine paradox” 
[48, 49]. There are also studies suggesting the participation 
of citrulline-arginine recycling via the citrulline-NO cycle in 
high-output production of NO in activated microglial cells 
and in endothelial cells [50]. 
4. L-ARGININE – NO PATHWAY IN CHRONIC 
HEART FAILURE 
  There is general consensus that the basic disturbance 
underlying the pathology of heart failure is the loss of 
functioning, necrotic or apoptotic myocardial cells, resulting 
in an inadequate blood flow to peripheral tissues [51, 52]. In 
this syndrome, a cascade of neurohormonal and hemody-
namic mechanisms, such as activation of the sympathetic 
system and renin-angiotensin-aldosterone system, are 
activated to preserve cardiac function. However, prolonged 
activation of these pathways is deleterious and is responsible 
for the development of chronic heart failure [51, 53]. 
Furthermore, increased oxidative stress and the presence of 
an inflammatory status may contribute further to cardiac 
remodelling and vascular dysfunction observed in this illness 
[54-57]. CHF is thus a very complex syndrome characterised 
by a myriad of cellular and systemic alterations. There is 
accumulating evidence that the L-arginine-NO pathway has 
an important role in the pathophysiology of this disorder [6]. 
  According to several studies, endothelial dysfunction 
could result from decreased release or enhanced inactivation 
of NO by increased oxidative stress found in CHF [3]. 
Therefore, disturbances of the L-arginine-NO pathway 
reported in CHF may have an important role in the 
pathogenesis of this syndrome (Table 1). Decreased activity 
of the L-arginine-NO pathway is suggested by reduced 
urinary excretion of nitrates in heart failure patients at rest 
and during exercise after infusion of L-[
15N]-arginine and by 
decreased eNOS expression and NO synthesis in the aortic 
endothelium from experimental rodent models of heart 
failure [58-61]. Clinical and animal models of CHF have 
reported increased plasma levels of ADMA, which would 
inhibit NO production and lead to decreased endothelium-
dependent relaxation [62-65]. Moreover, elevated levels of 
ADMA have been proposed as a predictor of adverse 
cardiovascular outcomes in patients with heart failure [66]. 
In contrast, several clinical studies have demonstrated that 
patients with heart failure exhibit an increased respon-
siveness to inhibitors of NO synthesis and elevated plasma 
levels of stable NO breakdown products [67-70], suggesting 
that NO synthesis is increased rather than decreased.  
  Furthermore, an activation of L-arginine uptake in 
erythrocytes and aorta were found in patients and in rodent 
models of heart failure, respectively [71, 72]. According to 
these findings, it is possible that the increment in L-arginine 
transport could represent an adaptive response to increase L-
arginine availability for a putative increase in basal NO 
production in heart failure. On the other hand, Kaye et al. 
[69] have shown an impairment of L-arginine uptake 
associated with the reduction of CAT-1 expression in 
myocardial cells from chronic heart failure patients. 
  Our group has detected the presence of a disturbance in 
the plasma amino acid profile in CHF, with concentrations of 
most amino acids lower compared to healthy age-matched 
controls [72]. The plasma levels of L-arginine in heart failure 
were reduced by 50% of control values (Table 1). In this 
context, increased L-arginine transport observed in erythro-
cytes from CHF patients may reflect a widespread 
compensatory response to the decreased plasma L-arginine 
to sustain elevated production of NO. We have also report 
that plasma levels of L-NMMA are elevated in CHF patients 
[72]. 
  The presence of nNOS, eNOS and iNOS have been 
detected in myocardium [73]. Increasing evidence indicates 
that expression and activity of iNOS is increased in different 
tissues and cells in heart failure [71, 74, 75]. In contrast, 
conflicting data exist with regard to eNOS expression and 
activity [73]. nNOS seems also to be involved in the 
pathogenesis of heart failure, and according to one study, 
myocardial cells from heart failure patients have an 
increased expression and activity of nNOS [76]. The reasons 
underlying conflicting findings in the L-arginine-NO 
pathway in chronic heart failure are unknown and may 
reflect the diverse causes and severity of this disease.  
5. EFFECTS OF EXERCISE IN HEART FAILURE 
PATIENTS 
  It is well known that exercise training leads to beneficial 
adaptations in patients with heart failure, including an 
improvement in symptoms and quality of life, reduction of 58    The Open Biochemistry Journal, 2009, Volume 3  Mendes-Ribeiro et al. 
Table 1.  Modulation of the L-Arginine-NO Pathway in Chronic Heart Failure 
  Reported Change  Summary of Findings  Reference 
Increased   plasma nitrate levels  Chowdhary, et al. 2002 
Increased   vasoconstrictor effect of L-NMMA  Dover et al. 2006 
Decreased  L-arginine administration  vascular resistance associated with  
nitrate/nitrite production 
Katz et al. 1999 
Increased   NO plasma concentration  Kaye et al. 1998 
Increased   iNOS expression in skeletal muscle  Stein et al. 1998 
Increased   iNOS expression and iNOS protein content in skeletal muscle inversely 
correlated with changes in COX-activity and the exercise 
Gielen et al. 2005 
Increased   endomyocardial eNOS or iNOS gene expression augments LV stroke 
volume and LV stroke work 
Heymes et al. 1999 
Decreased   activity of the L-arginine-NO metabolic pathway  Katz et al. 1999 
Increased   iNOS, but not eNOS expression in ventricular myocardium  Drexler et al. 1999 
Increased   plasma nitrite level  Yu et al. 2001 
Increased   iNOS expression in the myocardium and  serum concentration of 
nitrate/nitrite 
Orús et al. 2000 
Increased   NO plasmatic concentation which showed positive correlation with TNF- 
plasmatic levels 
Elahi et al. 2007 
Increased/decreased   iNOS activity and expression, but  eNOS activity and expression in 
failing hearts 
Ferreiro et al. 2004 
NOS activity/ NOS 
expression/ 
nitrite+nitrate 
production /cGMP 
Unaltered  There was no difference in exhaled NO between controls and heart failure 
patients, nor after exercise 
Seshadri et al. 2003 
Decreased   responses vasodilatador endothelium-dependent induce by acetylcholine in 
braquial artery 
Morgan et al. 2004 
Decreased   forearm blood flow  Ishibashi et al. 2000 
Decreased   vasodilatation endothelium-dependent in forearm  Heitzer et al. 2005 
Increased  Vitamin C improves endothelium-dependent forearm vasodilatation  Hirooka et al. 2003 
Decreased   endothelium-dependent vasodilatation in response to aceylcholine in 
internal radial artery was improved by oral L-arginine supplementation and 
exercise training. 
Hambrecht et al. 2000 
Decreased   forearm blood flow  Bank et al. 2000 
Endothelial function 
Decreased   forearm blood flow in response to acetylcholine.  Sugamori et al. 2002 
L-arginine transport  Increased   L-arginine transport via system y
+ in erythrocytes from heart failure 
patients associated with  plasmatic levels of L-arginine and  plasmatic 
levels of L-NMMA 
Hanssen et al. 1998 
L-NMMA, N
G-monomethyl L-arginine; NO, nitric oxide; NOS, nitric oxide synthase; iNOS, inducible nitric oxide synthase; eNOS, endothelial nitric oxide synthase; PBMCs, 
peripheral blood mononuclear cells; COX, cytochrome e oxidase. 
fatigue and dyspnea, and enhancement of exercise tolerance. 
Thus, exercise training is strongly recommended by the 
American Heart Association [14] and the European Society 
of Cardiology [2], as part of the treatment for mild to 
moderate heart failure. These patients usually have a very 
low exercise capacity with VO2 peak levels between 12 to 15 
mL.kg
-1.min
-1, approximately half of that observed in healthy 
individuals matched by age and gender [77]. Improving 
exercise tolerance, and consequently VO2peak, is important 
for two major reasons: (1) the minimum threshold for 
independent living is 18 and 15 mL.kg
-1.min
-1 for elderly 
men and women, respectively [78]; and (2) heart failure 
patients with VO2peak lower than 14 mL.kg
-1.min
-1 are 
candidates for heart transplantation [79].  
  There is an extensive body of knowledge regarding the 
positive effects of exercise on functional capacity, demon-
strated by an increase in VO2peak, an improvement in the New 
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life and functional autonomy [80]. The benefits are not 
restricted to the functional aspect, but extend to a lower 
mortality rate and to hospital readmission [81]. It is worth 
noting, however, that more conclusive data will be available 
after the termination of the trial Heart Failure: A Controlled 
Trial Investigating Outcomes of Exercise Training (HF-
ACTION). This is the largest trial investigating the effects of 
exercise on HF patients and has been conducted since 2002 
in more than 50 U.S. and Canadian hospitals involving 3000 
patients.  
  The causes of exercise intolerance and the precise 
mechanisms for the beneficial effects of exercise in heart 
failure are still being extensively discussed. It has been 
suggested that central (related to the heart) and peripheral 
(related to the muscle and the vasculature) factors, in 
addition to neurohormonal modifications, can contribute to 
exercise intolerance [82]. An in-depth review about the 
central, metabolic, and neurohormonal adaptations asso-
ciated with exercise training is beyond the scope of this 
review. 
  Exercise has also been shown to improve some 
alterations in neuro-hormonal overactivity found in CHF. A 
reduction in norepinephrine spillover, enhancement in the 
vagal high frequency component of heart rate variability, and 
a decrease in the sympathetically mediated low-frequency 
oscillation have been demonstrated. [83, 84]. Although 
controversial, it is possible that these effects of exercise are 
secondary to skeletal muscle or peripheral vascular training 
improvement [83-85]. Recently, consistent data has 
suggested that reduction in sympathetic nerve activity and 
improvement in baroreflex function in CHF after exercise 
are due to the concomitant reduction in angiotensin II and 
angiotensin receptors in the central nervous system [86]. 
5.1. Vascular Adaptations to Exercise in Heart Failure 
Patients: Role of L-Arginine-NO Pathway 
  Exercise intolerance can also result from the systemic 
vasoconstriction and diminished peripheral perfusion 
commonly seen in heart failure. In this context, the endothe-
lium, and especially NO, constitute central figures in 
vasomotor tone and perfusion regulation [87]. It has been 
consistently demonstrated that exercise training restores 
endothelium function in CHF patients. An increase in the 
brachial artery diameter [88] or in forearm blood flow [89] 
was observed after infusion of acetylcholine, but not by 
nitroglycerine or sodium nitroprussiate, indicating an 
improvement in endothelium-dependent and non–
independent vasodilation. Flow-dependent vasodilation is 
also increased after exercise training [90]. These changes 
were observed after at least 4 weeks of different exercise 
modes, including aerobic training on a cycle ergometer [87], 
local muscular endurance training (handgrip) [89] and circuit 
training involving resistance plus aerobic training [91]. Table 
2 presents a summary of the trials involving exercise and 
vascular changes in heart failure patients.  
  Although it is clear that exercise training enhances 
vascular endothelial function and particularly NO-mediated 
vasodilation, the molecular basis for this improvement has 
still not been completely elucidated. The preponderance of 
data suggests that a great part of the beneficial effects on 
vascular structure and reactivity are due to exercise-induced 
increases in endothelial shear stress. Exercise, by means of 
its transient increase in blood flow, affects the two forces 
acting on an artery. One is perpendicular to the wall and 
represents blood pressure, and the other acts parallel to the 
wall creating a frictional force at the surface of the 
endothelium, the so-called shear stress. Intra-arterial pressure 
seems to have little effect on endothelial control of 
vasoactivity; in contrast the principal regulator of arterial 
diameter is shear stress, mainly through NO release. 
  Acutely, shear stress mediates a biphasic production of 
NO with an initial rapid rise at the onset of flow, followed by 
a sustained increased level of production. The activation of 
eNOS occurs mainly through two mechanisms: calcium/ 
calmodulin, which dissociates eNOS from caveolin-1 [92], 
and phosphorylation of eNOS-S
1179 and eNOS-S
635 by 
protein kinase A, protein kinase B, and phosphoinositide-3-
kinase [93, 94]. Chronically, shear stress induces an increase 
in the eNOS expression level and cGMP production [95]. 
Supporting these studies in vitro, it was demonstrated that 
exercise training caused an increase in eNOS expression in 
aortic endothelial cells [96] and prevented its decrease in the 
exercising muscle [97] of heart failure animal models. 
Recently, shear stress has also been shown to augment 
tetrahydrobiopterin (BH4) levels and enzymatic activity of 
GTP cyclohydrolase-1, the first step of BH4 biosynthesis, in 
human endothelial cells [98]. 
  Although it is clear from studies in vitro and animal 
models in vivo that shear stress and physical exercise affect 
eNOS expression and BH4 levels, there is limited evidence 
from human studies involving CHF patients. To our 
knowledge, only one study has investigated this issue in 
humans and no changes in the steady-state transcription 
levels of eNOS, angiotensin converting enzyme, or 
prostacyclin synthase were detected in samples of vastus 
lateralis muscle after 12 weeks of moderate intensity 
endurance training [99]. On the other hand, the same study 
showed that exercise caused an 100% increase in gene 
expression of the antioxidant enzymes cupper/zinc supero-
xide dismutase (CuZnSOD) and glutathione peroxidise-1 
(GPx-1) [99]. Thus, the positive effects of exercise on the 
vasculature may be due to reduced oxidative stress rather 
than an increase in eNOS expression, leading to an increase 
in NO bioavailability. However, it does not seem to be a 
consistent finding, since Linke et al. reported that mRNA 
levels and protein expression of MnSOD, CuZnSOD, GPx-1 
and catalase (Cat) were unaltered after 6 months of training 
in samples of the vastus lateralis muscle of chronic heart 
failure patients [100]. These opposite findings might be due 
to different methods used to normalize mRNA transcripts of 
GPx-1 and CuZnSOD.  
  It is important to remember that further studies are 
needed to confirm these findings and also to investigate 
exercise induced changes in the expression and activity of 
eNOS and antioxidant enzymes in the endothelium and other 
cell types. Exercise may also affect another step involved in 
NO synthesis from L-arginine. After 8 weeks of endurance 
training at 50 to 60 % of maximum heart rate, L-arginine 
transport, measured by the clearance rate of L-[
3H]-arginine, 
increased in heart failure patients associated with an 
improvement in endothelial function [101]. 60    The Open Biochemistry Journal, 2009, Volume 3  Mendes-Ribeiro et al. 
Table 2  Effects of Exercise in Heart Failure Patients 
Subjects Exercise  Results  Ref. 
52 M (55±10 yr) 
EF = 31±7% 
NYHA II / III 
8 wk. Aerobic 
60% VO2peak 
3 x 40 min 
 VO2peak 
Sig. correlation between changes in VO2peak and 
EDVD 
 FDVD 
 EIVD  
Belardinelli et al. 2006 
12 (60±2 yr) 
NYHA I/II 
EF=26±3% 
8 wk 
Resistance (55-65% 1RM)+ aerobic  
70-85% HRpeak 
3 x 60 min 
 VO2peak 
 EDVD  
 EIVD  
Maiorana et al. 2000  
10 M (55±4 yr) 
NYHA II/III 
EF=19±9% 
4 wk. Handgrip training 
60 N 
6x/day 
 EDVD  
 FDVD 
 EIVD  
Hambrecht et al. 2000  
10 (54±4 yr) 
EF=24±4% 
NYHA II/III 
24 wk. Aerobic 
5x40 min 
70% VO2peak 
 VO2peak 
 forearm BF (ACh) 
 forearm BF (NTG) 
 BF velocity 
 inhibitory effect of L-NMMA on forearm BF 
Hambrecht et al. 1998  
12 (10 M, 58±3 yr) 
EF=25±5% 
NYHA II/III 
8 wk. Handgrip 
5x30 min 
70% maximal work rate 
20 cont/min 
 forearm BF (ACh) 
 forearm BF (NTG) 
 reactive forearm BF  
Katz et al. 1997  
11 M (55±10 yr) 
EF = 26±3% 
NYHA II / III 
6x/day. Aerobic 
10 min 
70% VO2peak 
 VO2peak 
 EDVD  
 FDVD 
 EIVD  
Linke et al. 2001 
14 (62±6 yr) 
EF=34±9% 
12 wk. Aerobic 
50% VO2peak 
4x45 min 
 VO2peak 
 Cu/Zn SOD and GSH-Px gene expression 
 steady-state transcript levels for eNOS, ACE, 
PGI2S 
Ennezat et al. 2001 
10 M (55±2 yr) 
EF=26±3% 
NYHA II/III 
6 mo. Aerobic. 
5x20min 
70% VO2peak 
 VO2peak 
 iNOS expression and protein content in skeletal 
muscle 
 skeletal muscle nitrotyrosine content 
 cytochrome coxidase activity 
Gielen et al. 2005  
10 M (55±2 yr) 
EF=26±3% 
NYHA II/III 
6 mo. Aerobic. 
5x20min 
70% VO2peak 
 VO2peak 
 TNF-, IL-6, IL-1- mRNA, iNOS expression 
in skeletal muscle 
 serum cytokine levels 
Gielen et al. 2003  
11 M (55±3 yr) 
EF = 21±2% 
NYHA II / III 
8 wk. Aerobic.  
50-60% HRmax 
3-5x30-60 min 
 6-min walk distance 
 forearm BF (ACh) 
 forearm BF (NTG) 
 L-arg transport 
 plasma L-arginine, L-citrulline, ADMA, 
SDMA 
Parnell et al. 2005 
12 M (55±2 yr) 
EF=26±3% 
NHYA II/III 
6 mo. Aerobic. 
5x20min 
70% VO2peak 
 VO2peak 
 Mn and Cu/Zn SOD activity, mRNA content, 
or protein expression in skeletal muscle 
 Cat activity,  Cat mRNA or protein 
expression 
 GPX activity,  GPX mRNA or protein 
expression 
 lipid peroxidation 
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(Table 2). Contd….. 
Subjects Exercise  Results  Ref. 
24 (55±2yr) 
EF: 23±1% 
NYHA II/III 
12 wk. Aerobic. 
60-80% HRmax 
5x30min 
 VO2peak 
 serum TNF-, sTNFR1, sTNFR2, IL-6. sIL-
6R, sFas, sFasL 
Adamopoulos et al. 
2002  
23 (27-78 yr) 
EF: 11-45% 
NYHA I-IV 
4 mo. 3x/wk 
Aerobic+RT 
Aerobic: 20min 90% VT 
RT: 2x10 reps 50% 1RM 
 VO2peak 
 NYHA class 
 serum TNF-, IL-6 
 sTNFR1, sTNFR2 (DAC) 
Conraads et al. 2002  
18 (54±9 yr) 
NHYA 2.2±0.7 
8 wk. Aerobic. 
5x20 min 
70-80% HRmax 
Calistenics 
 VO2peak 
 plasma TNF-, TNF-R 1 and 2, IL-6, e-
selectin, sICAM, sCD14 
Niebauer et al. 2005  
ADMA = asymmetric dimethylarginine; CAD = coronary arterial disease; M = men; EF = ejection fraction; NYHA = New York Heart Association; EDVD = endothelium dependent 
vasodilation; FDVD = flow dependent vasodilation; EIVD = endothelium independent vasodilation; BF = blood flow; ACh = acetylcoline; NTG = nitroglycerine; L-NMMA = N
G-
monomethyl-L-arginine; SOD = superoxide dismutase; GSH-Px = glutathione-peroxidase; eNOS = endothelial nitric oxide synthase; iNOS = inducible nitric oxide synthase; ACE = 
angiotensin-converting enzyme; PGI2 = prostacyclin; cont = contraction; wk = week. 
 
  In addition to its effect on vasomotion, NO is known to 
antagonize key processes involved in thrombus formation, 
including monocyte adherence and chemotaxis, platelet 
adhesion and aggregation, and vascular smooth cell 
proliferation (Moncada et al., 2006; Brunini et al., 2007). 
Therefore, another potential favourable effect of exercise, 
though not confirmed by long-term studies, would be a 
reduction in the incidence of thrombotic events, which is 
higher in heart failure patients than in the general population. 
In healthy individuals, a reduction in platelet aggregation 
induced by oxidized LDL after 8 weeks of aerobic training 
was shown [102].  
5.2. Exercise and Inflammation in Heart Failure 
  There is convincing evidence that inflammatory 
mediators play an important role in skeletal muscle wasting 
and fatigue in heart failure [103]. Among the cytokines, TNF 
particularly has been shown to provoke net nitrogen loss and 
catabolism when administered to experimental animals 
[104]. In skeletal muscle biopsies from heart failure patients, 
the cytokines interleukin IL1- and TNF- can induce a 
pathological increase in iNOS in skeletal muscle via 
activation of nuclear factor kappa B (NFB) [105]. High 
iNOS-derived NO concentrations in skeletal muscle may 
inhibit key aerobic enzymes such as cytochrome c oxidase, 
impairing cellular respiration and causing structural damage 
to the mitochondria [106]. 
  Despite all of the positive actions of NO that have been 
highlighted, overproduction of NO can lead to serious 
cytotoxic effects in the skeletal muscle and even the heart 
[107]. Long-term aerobic training causes a reduction in the 
inflammatory state of skeletal muscle, as evidenced by a 
diminished expression of TNF-, IL-6 and IL-1-beta mRNA 
expression [108]. Consequently, there is a reduction in iNOS 
expression and protein nitrotyrosine content, a marker of 
peroxynitrite formation from NO and superoxide radical, in 
exercised skeletal muscle from heart failure patients [109]. 
These findings were inversely associated with an increase in 
cytocrome c oxidase activity, reflecting an improvement in 
muscular oxidative metabolism and increased VO2peak. 
Except for one paper published by Adamopoulos et al. [110], 
serum concentrations of cytokines and their receptors do not 
seem to decrease after physical training [109, 111, 112], 
suggesting that changes in local cytokine expression occur 
earlier than in the circulating system. 
  Plasma levels of cytokines, particularly TNF-, IL-1 and 
IL-6, are elevated in CHF patients and may play a role in the 
genesis and progression of heart failure [113-117]. The 
increase in circulating concentrations of TNF- and IL-6 
correlated directly with the severity of the disease and with 
death and inversely with exercise tolerance in CHF [117-
120]. At the cardiac level, the overexpression of cytokines, 
induced by a variety of stressors, promotes contractile 
dysfunction, impaired  adrenergic receptor sensitivity, 
alterations in vascular endothelium and recruitment of 
additional circulating inflamed cells in injured myocardium 
[114, 121]. Moreover, a long-term presence of these 
inflammatory mediators results in myocyte phenotype 
transition and activation of matrix metalloproteinases, which 
modifies the interstitial matrix, further increasing the 
remodeling process [122]. Studies in vivo also suggest that 
the death of apoptotic myocytes after sustained TNF 
signaling is a consequence the depletion of one or more 
antiapoptotic cytoprotective proteins [123]. 
  Exercise training, particularly endurance exercise, has 
been shown to promote a decrease in oxidative stress and 
inflammation which can interfere in NOS activity and 
expression. Nevertheless, it is important to highlight that the 
benefits of exercise on vascular tone and muscle perfusion 
through its effects on NO bioavailability can explain only 
part of the benefits conferred by exercise training. Vascular 
tone can also be influenced by sympathetic activity and 
hormonal factors, and both can also be positively affected by 
regular exercise.  
6. CONCLUSION 
  In this review, we critically examined the mechanisms 
underlying chronic heart failure and potential clinical 
benefits of exercise. The endothelial dysfunction present in 
CHF, partly reversed by exercise, is involved in widespread 
vasoconstriction in heart failure. It seems that interfering 
with L-arginine-NO pathway, inflammation and free radical 62    The Open Biochemistry Journal, 2009, Volume 3  Mendes-Ribeiro et al. 
metabolism may be useful adaptations to training in CHF 
patients. 
ACKNOWLEDGEMENT 
  We acknowledge financial support from FAPERJ and 
PQ-CNPq. 
REFERENCES 
[1]  Mann, D.L.; Bristow, M.R. Mechanisms and models in heart 
failure: the biomechanical model and beyond. Circulation, 2005, 
111, 2837-2849. 
[2]  Dickstein, K.; Cohen-Solal, A.; Filippatos, G.; McMurray, J. J.; 
Ponikowski, P.; Poole-Wilson, P. A.; Stromberg, A.; van 
Veldhuisen, D. J.; Atar, D.; Hoes, A. W.; Keren, A.; Mebazaa, A.; 
Nieminen, M.; Priori, S. G.; Swedberg, K.; Vahanian, A.; Camm, 
J.; De Caterina, R.; Dean, V.; Funck-Brentano, C.; Hellemans, I.; 
Kristensen, S. D.; McGregor, K.; Sechtem, U.; Silber, S.; Tendera, 
M.; Widimsky, P.; Zamorano, J. L.; Auricchio, A.; Bax, J.; Bohm, 
M.; Corra, U.; Della Bella, P.; Elliott, P. M.; Follath, F.; 
Gheorghiade, M.; Hasin, Y.; Hernborg, A.; Jaarsma, T.; Komajda, 
M.; Kornowski, R.; Piepoli, M.; Prendergast, B.; Tavazzi, L.; 
Vachiery, J. L.; Verheugt, F. W.; Zannad, F. ESC Guidelines for 
the diagnosis and treatment of acute and chronic heart failure 2008: 
The Task Force for the Diagnosis and Treatment of Acute and 
Chronic Heart Failure 2008 of the European Society of Cardiology. 
Developed in collaboration with the Heart Failure Association of 
the ESC (HFA) and endorsed by the European Society of Intensive 
Care Medicine (ESICM). Eur. Heart J., 2008, 10, 933-989. 
[3]  Landmesser, U.; Drexler, H. The clinical significance of 
endothelial dysfunction. Curr. Opin. Cardiol., 2005, 20, 547-551. 
[4]  Carville, C.; Adnot, S.; Sediame, S.; Benacerraf, S.; Castaigne, A.; 
Calvo, F.; de Cremou, P.; Dubois-Rande, J. L. Relation between 
impairment in nitric oxide pathway and clinical status in patients 
with congestive heart failure. J. Cardiovasc. Pharmacol., 1998, 32, 
562-570. 
[5]  Stewart, D.J. Nitric oxide puzzles and paradoxes in heart failure: 
how to fit the pieces together? Clin. Sci. Lond., 1998, 94, 3-4. 
[6]  Mendes Ribeiro, A. C.; Brunini, T. M.; Ellory, J. C.; Mann, G. E. 
Abnormalities in L-arginine transport and nitric oxide biosynthesis 
in chronic renal and heart failure. Cardiovasc. Res., 2001, 49, 697-
712. 
[7]  Palmer, R.M.; Rees, D.D.; Ashton, D.S.; Moncada, S. L-arginine is 
the physiological precursor for the formation of nitric oxide in 
endothelium-dependent relaxation. Biochem. Biophys.  Res. 
Commun., 1988, 153, 1251-1256. 
[8]  Bredt, D. S.; Hwang, P. M.; Glatt, C. E.; Lowenstein, C.; Reed, R. 
R.; Snyder, S. H. Cloned and expressed nitric oxide synthase 
structurally resembles cytochrome P-450 reductase. Nature, 1991, 
351, 714-718. 
[9]  Moncada, S. Adventures in vascular biology: a tale of two 
mediators. Philos. Trans. R. Soc. Lond. B. Biol. Sci., 2006, 361, 
735-759. 
[10]  Ignarro, L. J. Heme-dependent activation of guanylate cyclase by 
nitric oxide: a novel signal transduction mechanism. Blood Vessels, 
1991, 28, 67-73. 
[11]  Rush, J. W.; Denniss, S. G.; Graham, D. A. Vascular nitric oxide 
and oxidative stress: determinants of endothelial adaptations to 
cardiovascular disease and to physical activity. Can. J . Appl. 
Physiol., 2005, 30, 442-474. 
[12]  Piepoli, M. F. Exercise training in heart failure. Curr.  Cardiol. 
Rep., 2005, 7, 216-222. 
[13]  Jessup, M.; Brozena, S., Heart failure. N. Engl. J. Med., 2003, 348, 
2007-2018. 
[14]  Hunt, S.A.; Abraham, W.T.; Chin, M.H.; Feldman, A.M.; Francis, 
G.S.; Ganiats, T. G.; Jessup, M.; Konstam, M.A.; Mancini, D.M.; 
Michl, K.; Oates, J.A.; Rahko, P.S.; Silver, M.A.; Stevenson, L.W.; 
Yancy, C.W.; Antman, E.M.; Smith, S.C., Jr.; Adams, C.D.; 
Anderson, J.L.; Faxon, D.P.; Fuster, V.; Halperin, J.L.; Hiratzka, 
L.F.; Jacobs, A. K.; Nishimura, R.; Ornato, J.P.; Page, R.L.; Riegel, 
B.; American College of C.; American Heart Association Task 
Force on Practice, G.; American College of Chest, P.; International 
Society for, H.; Lung, T.; Heart Rhythm, S., ACC/AHA 2005 
Guideline Update for the Diagnosis and Management of Chronic 
Heart Failure in the Adult: a report of the American College of 
Cardiology/American Heart Association Task Force on Practice 
Guidelines (Writing Committee to Update the 2001 Guidelines for 
the Evaluation and Management of Heart Failure): developed in 
collaboration with the American College of Chest Physicians and 
the International Society for Heart and Lung Transplantation: 
endorsed by the Heart Rhythm Society. Circulation,  2005,  112, 
e154-235. 
[15]  Francis, G. S.; Tang, W.H. Pathophysiology of congestive heart 
failure. Rev. Cardiovasc. Med., 2003, 4 (Suppl 2), S14-20. 
[16]  Katz, A.M. Heart failure: a hemodynamic disorder complicated by 
maladaptive proliferative responses. J. Cell Mol. Med., 2003, 7, 1-
10. 
[17]  Anand, I.S. Pathogenesis of salt and water retention in the 
congestive heart failure syndrome. In The heart failure, Philip 
Poole-Wilson, Ed.; Churchill-Livingstone: London, 1997; pp. 155-
171. 
[18] Ferreira,  M.E.  Insuficiência cardíaca, 1st ed.; Rubio: Rio de 
Janeiro, 2007. 
[19]  Eichhorn, E.J.; Bristow, M.R. Medical therapy can improve the 
biological properties of the chronically failing heart. A new era in 
the treatment of heart failure. Circulation, 1996, 94, 2285-2296. 
[20]  Sutton, M.G.; Sharpe, N. Left ventricular remodeling after 
myocardial infarction: pathophysiology and therapy. Circulation, 
2000, 101, 2981-2988. 
[21]  Ignarro, L.J.; Buga, G.M.; Wood, K.S.; Byrns, R.E.; Chaudhuri, G. 
Endothelium-derived relaxing factor produced and released from 
artery and vein is nitric oxide. Proc. Natl. Acad. Sci. USA, 1987, 
84, 9265-9269. 
[22]  Moncada, S.; Palmer, R.M.; Higgs, E.A. Biosynthesis of nitric 
oxide from L-arginine. A pathway for the regulation of cell 
function and communication. Biochem. Pharmacol.,  1989,  38, 
1709-1715. 
[23]  Marletta, M.A. Nitric oxide synthase: aspects concerning structure 
and catalysis. Cell, 1994, 78, 927-930. 
[24]  Archer, S. Measurement of nitric oxide in biological models. 
FASEB J. 1993, 7, 349-360. 
[25]  Bryan, N.S.; Grisham, M.B. Methods to detect nitric oxide and its 
metabolites in biological samples. Free Radic. Biol. Med., 2007, 
43, 645-657. 
[26]  Gross, R.; Roye, M.; Manteghetti, M.; Broca, C.; Hillaire-Buys, D.; 
Masiello, P.; Ribes, G. Mechanisms involved in the effect of nitric 
oxide synthase inhibition on L-arginine-induced insulin secretion. 
Br. J. Pharmacol., 1997, 120, 495-501. 
[27]  Dudzinski, D.M.; Igarashi, J.; Greif, D.; Michel, T. The regulation 
and pharmacology of endothelial nitric oxide synthase. Annu. Rev. 
Pharmacol. Toxicol., 2006, 46, 235-276. 
[28]  Ghafourifar, P.; Richter, C. Nitric oxide synthase activity in 
mitochondria. FEBS Lett., 1997, 418, 291-296. 
[29]  Kanai, A.J.; Pearce, L.L.; Clemens, P.R.; Birder, L.A.; VanBibber, 
M.M.; Choi, S. Y.; de Groat, W.C.; Peterson, J. Identification of a 
neuronal nitric oxide synthase in isolated cardiac mitochondria 
using electrochemical detection. Proc. Natl. Acad. Sci. USA, 2001, 
98, 14126-14131. 
[30]  Valdez, L.B.; Boveris, A. Mitochondrial nitric oxide synthase, a 
voltage-dependent enzyme, is responsible for nitric oxide diffusion 
to cytosol. Front. Biosci., 2007, 12, 1210-1219. 
[31]  Boveris, A.; Valdez, L.B.; Alvarez, S.; Zaobornyj, T.; Boveris, 
A.D.; Navarro, A. Kidney mitochondrial nitric oxide synthase. 
Antioxid. Redox. Signal., 2003, 5, 265-271. 
[32]  Elfering, S.L.; Sarkela, T.M.; Giulivi, C. Biochemistry of 
mitochondrial nitric-oxide synthase. J. Biol. Chem.,  2002,  277, 
38079-38086. 
[33]  Valdez, L.B.; Zaobornyj, T.; Boveris, A. Mitochondrial metabolic 
states and membrane potential modulate mtNOS activity. Biochim. 
Biophys. Acta, 2006, 1757, 166-172. 
[34]  Roy, B.; Garthwaite, J. Nitric oxide activation of guanylyl cyclase 
in cells revisited. Proc. Natl. Acad. Sci. USA, 2006, 103, 12185-
12190. 
[35]  Boerrigter, G.; Lapp, H.; Burnett, J.C. Modulation of cGMP in 
heart failure: a new therapeutic paradigm. Handb. Exp. 
Pharmacol., 2009, 485-506. 
[36]  Simonsen, U.; Rodriguez-Rodriguez, R.; Dalsgaard, T.; Buus, N. 
H.; Stankevicius, E. Novel approaches to improving endothelium-
dependent nitric oxide-mediated vasodilatation. Pharmacol. Rep. 
2009, 61, 105-115. Heart Failure, Nitric Oxide and Exercise  The Open Biochemistry Journal, 2009, Volume 3    63 
[37]  Sakurada, M.; Shichiri, M.; Imamura, M.; Azuma, H.; Hirata, Y. 
Nitric oxide upregulates dimethylarginine dimethylaminohy-
drolase-2  via  cyclic GMP induction in endothelial cells. 
Hypertension, 2008, 52, 903-909. 
[38]  Morris, S.M., Jr. Recent advances in arginine metabolism. Curr. 
Opin. Clin. Nutr. Metab. Care, 2004, 7, 45-51. 
[39]  Reyes, A.A.; Karl, I.E.; Yates, J.; Klahr, S. Low plasma and renal 
tissue levels of L-arginine in rats with obstructive nephropathy. 
Kidney Int., 1994, 45, 782-787. 
[40]  Mendes Ribeiro, A. C.; Brunini, T. M., L-Arginine transport in 
disease. Curr. Med. Chem. Cardiovasc. Hematol. Agents, 2004, 2, 
123-131. 
[41]  Ignarro, L.J.; Napoli, C.; Loscalzo, J. Nitric oxide donors and 
cardiovascular agents modulating the bioactivity of nitric oxide: an 
overview. Circ. Res. 2002, 90, 21-28. 
[42]  Mann, G. E.; Yudilevich, D. L.; Sobrevia, L. Regulation of amino 
acid and glucose transporters in endothelial and smooth muscle 
cells. Physiol. Rev., 2003, 83, 183-252. 
[43]  Shibazaki, T.; Fujiwara, M.; Sato, H.; Fujiwara, K.; Abe, K.; 
Bannai, S. Relevance of the arginine transport activity to the nitric 
oxide synthesis in mouse peritoneal macrophages stimulated with 
bacterial lipopolysaccharide. Biochim. Biophys. Acta, 1996, 1311, 
150-154. 
[44]  Stevens, B.R.; Kakuda, D.K.; Yu, K.; Waters, M.; Vo, C.B.; 
Raizada, M.K. Induced nitric oxide synthesis is dependent on 
induced alternatively spliced CAT-2 encoding L-arginine transport 
in brain astrocytes. J. Biol. Chem., 1996, 271, 24017-24022. 
[45]  Bogle, R.G.; Baydoun, A.R.; Pearson, J.D.; Mann, G.E. Regulation 
of L-arginine transport and nitric oxide release in superfused 
porcine aortic endothelial cells. J. Physiol., 1996, 490(Pt 1), 229-
241. 
[46]  Mendes Ribeiro, A.C.; Brunini, T.M.; Yaqoob, M.; Aronson, J.K.; 
Mann, G.E.; Ellory, J.C. Identification of system y+L as the high-
affinity transporter for L-arginine in human platelets: up-regulation 
of L-arginine influx in uraemia. Pflugers Arch., 1999, 438, 573-
575. 
[47]  Zani, B.G.; Bohlen, H.G. Transport of extracellular l-arginine via 
cationic amino acid transporter is required during in vivo 
endothelial nitric oxide production. Am. J. Physiol. Heart Circ. 
Physiol., 2005, 289, H1381-1390. 
[48]  Wyatt, A.W.; Steinert, J.R.; Mann, G.E. Modulation of the L-
arginine/nitric oxide signalling pathway in vascular endothelial 
cells. Biochem. Soc. Symp., 2004, 143-156. 
[49]  Vukosavljevic, N.; Jaron, D.; Barbee, K.A.; Buerk, D.G. 
Quantifying the L-arginine paradox in vivo. Microvasc. Res., 2006, 
71, 48-54. 
[50]  Kawahara, K.; Gotoh, T.; Oyadomari, S.; Kajizono, M.; Kuniyasu, 
A.; Ohsawa, K.; Imai, Y.; Kohsaka, S.; Nakayama, H.; Mori, M. 
Co-induction of argininosuccinate synthetase, cationic amino acid 
transporter-2, and nitric oxide synthase in activated murine 
microglial cells. Brain Res. Mol. Brain Res., 2001, 90, 165-173. 
[51]  Packer, M. Pathophysiology of chronic heart failure. Lancet, 1992, 
340, 88-92. 
[52]  Tavernarakis, N. Cardiomyocyte necrosis: alternative mechanisms, 
effective interventions. Biochim. Biophys. Acta, 2007, 1773, 480-
482. 
[53]  Mercadier, J. J. [Current pathophysiologic approaches to heart 
failure]. Presse Med., 2007, 36, 979-984. 
[54]  Grieve, D. J.; Shah, A. M. Oxidative stress in heart failure. More 
than just damage. Eur. Heart J. 2003, 24, 2161-2163. 
[55]  Hoare, G.S.; Birks, E.J.; Bowles, C.; Marczin, N.; Yacoub, M.H. In 
vitro endothelial cell activation and inflammatory responses in end-
stage heart failure. J. Appl. Physiol., 2006, 101, 1466-1473. 
[56]  Parodi, O.; De Maria, R.; Roubina, E. Redox state, oxidative stress 
and endothelial dysfunction in heart failure: the puzzle of nitrate-
thiol interaction. J. Cardiovasc. Med., 2007, 8, 765-774. 
[57]  Vila, V.; Martinez-Sales, V.; Almenar, L.; Lazaro, I. S.; Villa, P.; 
Reganon, E. Inflammation, endothelial dysfunction and 
angiogenesis markers in chronic heart failure patients. Int. J . 
Cardiol., 2008, 130, 276-277. 
[58]  Comini, L.; Bachetti, T.; Gaia, G.; Pasini, E.; Agnoletti, L.; Pepi, 
P.; Ceconi, C.; Curello, S.; Ferrari, R., Aorta and skeletal muscle 
NO synthase expression in experimental heart failure. J. Mol. Cell 
Cardiol., 1996, 28, 2241-2248. 
[59]  Habib, F.M.; Springall, D.R.; Davies, G.J.; Oakley, C.M.; Yacoub, 
M.H.; Polak, J. M., Tumour necrosis factor and inducible nitric 
oxide synthase in dilated cardiomyopathy. Lancet,  1996,  347, 
1151-1155. 
[60]  Katz, S.D.; Khan, T.; Zeballos, G.A.; Mathew, L.; Potharlanka, P.; 
Knecht, M.; Whelan, J. Decreased activity of the L-arginine-nitric 
oxide metabolic pathway in patients with congestive heart failure. 
Circulation, 1999, 99, 2113-2117. 
[61]  Wiemer, G.; Itter, G.; Malinski, T.; Linz, W. Decreased nitric oxide 
availability in normotensive and hypertensive rats with failing 
hearts after myocardial infarction. Hypertension, 2001, 38, 1367-
1371. 
[62]  Saitoh, M.; Osanai, T.; Kamada, T.; Matsunaga, T.; Ishizaka, H.; 
Hanada, H.; Okumura, K. High plasma level of asymmetric 
dimethylarginine in patients with acutely exacerbated congestive 
heart failure: role in reduction of plasma nitric oxide level. Heart 
Vessels, 2003, 18, 177-182. 
[63]  Feng, Q.; Lu, X.; Fortin, A.J.; Pettersson, A.; Hedner, T.; Kline, 
R.L.; Arnold, J. M. Elevation of an endogenous inhibitor of nitric 
oxide synthesis in experimental congestive heart failure. 
Cardiovasc. Res., 1998, 37, 667-675. 
[64]  Usui, M.; Matsuoka, H.; Miyazaki, H.; Ueda, S.; Okuda, S.; 
Imaizumi, T. Increased endogenous nitric oxide synthase inhibitor 
in patients with congestive heart failure. Life Sci., 1998, 62, 2425-
2430. 
[65]  Kielstein, J.T.; Bode-Boger, S.M.; Klein, G.; Graf, S.; Haller, H.; 
Fliser, D. Endogenous nitric oxide synthase inhibitors and renal 
perfusion in patients with heart failure. Eur. J. Clin. Invest., 2003, 
33, 370-375. 
[66]  Duckelmann, C.; Mittermayer, F.; Haider, D.G.; Altenberger, J.; 
Eichinger, J.; Wolzt, M. Asymmetric dimethylarginine enhances 
cardiovascular risk prediction in patients with chronic heart failure. 
Arterioscler. Thromb. Vasc. Biol., 2007, 27, 2037-2042. 
[67]  Dover, A.R.; Chia, S.; Ferguson, J.W.; Cruden, N.L.; Megson, I.L.; 
Fox, K.A.; Newby, D.E. Inducible nitric oxide synthase activity 
does not contribute to the maintenance of peripheral vascular tone 
in patients with heart failure. Clin. Sci. (Lond) 2006, 111, 275-280. 
[68]  Chowdhary, S.; Harrington, D.; Bonser, R.S.; Coote, J.H.; 
Townend, J.N. Chronotropic effects of nitric oxide in the 
denervated human heart. J. Physiol., 2002, 541, 645-651. 
[69]  Kaye, D.M.; Ahlers, B.A.; Autelitano, D.J.; Chin-Dusting, J.P. In 
vivo and in vitro evidence for impaired arginine transport in human 
heart failure. Circulation, 2000, 102, 2707-2712. 
[70]  Yu, C.M.; Fung, P.C.; Chan, G.; Lai, K.W.; Wang, Q.; Lau, C.P. 
Plasma nitric oxide level in heart failure secondary to left 
ventricular diastolic dysfunction. Am. J. Cardiol., 2001, 88, 867-
870. 
[71]  Stathopulos, P.B.; Lu, X.; Shen, J.; Scott, J.A.; Hammond, J.R.; 
McCormack, D. G.; Arnold, J.M.; Feng, Q. Increased L-arginine 
uptake and inducible nitric oxide synthase activity in aortas of rats 
with heart failure. Am. J. Physiol. Heart Circ. Physiol. 2001, 280, 
H859-867. 
[72]  Hanssen, H.; Brunini, T.M.; Conway, M.; Banning, A.P.; Roberts, 
N.B.; Mann, G. E.; Ellory, J.C.; Mendes Ribeiro, A.C. Increased L-
arginine transport in human erythrocytes in chronic heart failure. 
Clin. Sci., 1998, 94, 43-48. 
[73]  Seddon, M.; Shah, A.M.; Casadei, B. Cardiomyocytes as effectors 
of nitric oxide signalling. Cardiovasc. Res., 2007, 75, 315-326. 
[74]  Gealekman, O.; Abassi, Z.; Rubinstein, I.; Winaver, J.; Binah, O. 
Role of myocardial inducible nitric oxide synthase in contractile 
dysfunction and beta-adrenergic hyporesponsiveness in rats with 
experimental volume-overload heart failure. Circulation,  2002, 
105, 236-243. 
[75]  Ferreiro, C.R.; Chagas, A.C.; Carvalho, M.H.; Dantas, A.P.; 
Scavone, C.; Souza, L. C.; Buffolo, E.; da Luz, P.L. Expression of 
inducible nitric oxide synthase is increased in patients with heart 
failure due to ischemic disease. Braz. J. Med. Biol. Res., 2004, 37, 
1313-1320. 
[76]  Damy, T.; Ratajczak, P.; Shah, A.M.; Camors, E.; Marty, I.; 
Hasenfuss, G.; Marotte, F.; Samuel, J.L.; Heymes, C. Increased 
neuronal nitric oxide synthase-derived NO production in the failing 
human heart. Lancet, 2004, 363, 1365-1367. 
[77]  Warburton, D.E.; Taylor, A.; Bredin, S.S.; Esch, B.T.; Scott, J.M.; 
Haykowsky, M. J. Central haemodynamics and peripheral muscle 
function during exercise in patients with chronic heart failure. Appl. 
Physiol. Nutr. Metab., 2007, 32, 318-331. 64    The Open Biochemistry Journal, 2009, Volume 3  Mendes-Ribeiro et al. 
[78]  Paterson, D.H.; Govindasamy, D.; Vidmar, M.; Cunningham, D.A.; 
Koval, J.J. Longitudinal study of determinants of dependence in an 
elderly population. J. Am. Geriatr. Soc., 2004, 52, 1632-1638. 
[79]  Costanzo, M. R.; Augustine, S.; Bourge, R.; Bristow, M.; 
O'Connell, J. B.; Driscoll, D.; Rose, E. Selection and treatment of 
candidates for heart transplantation. A statement for health 
professionals from the Committee on Heart Failure and Cardiac 
Transplantation of the Council on Clinical Cardiology, American 
Heart Association. Circulation, 1995, 92, 3593-3612. 
[80]  Pina, I.L.; Apstein, C.S.; Balady, G.J.; Belardinelli, R.; Chaitman, 
B.R.; Duscha, B. D.; Fletcher, B.J.; Fleg, J.L.; Myers, J.N.; 
Sullivan, M.J. American Heart Association Committee on exercise, 
r.; prevention, Exercise and heart failure: A statement from the 
American Heart Association Committee on exercise, rehabilitation, 
and prevention. Circulation, 2003, 107, 1210-1225. 
[81]  Belardinelli, R.; Georgiou, D.; Cianci, G.; Purcaro, A. 
Randomized, controlled trial of long-term moderate exercise 
training in chronic heart failure: effects on functional capacity, 
quality of life, and clinical outcome. Circulation, 1999, 99, 1173-
1182. 
[82]  Keteyian, S. J. Exercise rehabilitation in chronic heart failure. 
Coron. Artery Dis., 2006, 17, 233-237. 
[83]  Coats, A.J. A sympathetic heart and the art of dying. Eur. Heart J., 
2001, 22, 1069-1071. 
[84]  Negrao, C.E.; Middlekauff, H.R. Adaptations in autonomic 
function during exercise training in heart failure. Heart Fail. Rev., 
2008, 13, 51-60. 
[85]  Wallin, B. G.; Charkoudian, N. Sympathetic neural control of 
integrated cardiovascular function: insights from measurement of 
human sympathetic nerve activity. Muscle Nerve, 2007, 36, 595-
614. 
[86]  Mousa, T. M.; Liu, D.; Cornish, K. G.; Zucker, I. H., Exercise 
training enhances baroreflex sensitivity by an angiotensin II-
dependent mechanism in chronic heart failure. J. Appl. Physiol. 
2008, 104, 616-624. 
[87]  Hambrecht, R.; Fiehn, E.; Weigl, C.; Gielen, S.; Hamann, C.; 
Kaiser, R.; Yu, J.; Adams, V.; Niebauer, J.; Schuler, G. Regular 
physical exercise corrects endothelial dysfunction and improves 
exercise capacity in patients with chronic heart failure. Circulation, 
1998, 98, 2709-2715. 
[88]  Hambrecht, R.; Hilbrich, L.; Erbs, S.; Gielen, S.; Fiehn, E.; 
Schoene, N.; Schuler, G. Correction of endothelial dysfunction in 
chronic heart failure: additional effects of exercise training and oral 
L-arginine supplementation. J. Am. Coll. Cardiol., 2000, 35, 706-
713. 
[89]  Katz, S.D.; Yuen, J.; Bijou, R.; LeJemtel, T.H. Training improves 
endothelium-dependent vasodilation in resistance vessels of 
patients with heart failure. J. Appl. Physiol., 1997, 82, 1488-1492. 
[90]  Linke, A.; Schoene, N.; Gielen, S.; Hofer, J.; Erbs, S.; Schuler, G.; 
Hambrecht, R. Endothelial dysfunction in patients with chronic 
heart failure: systemic effects of lower-limb exercise training. J. 
Am. Coll. Cardiol., 2001, 37, 392-397. 
[91]  Maiorana, A.; O'Driscoll, G.; Dembo, L.; Cheetham, C.; Goodman, 
C.; Taylor, R.; Green, D. Effect of aerobic and resistance exercise 
training on vascular function in heart failure. Am. J. physiol. Heart 
Circ. Physiol., 2000, 279, H1999-2005. 
[92]  Rizzo, V.; McIntosh, D.P.; Oh, P.; Schnitzer, J.E. In situ flow 
activates endothelial nitric oxide synthase in luminal caveolae of 
endothelium with rapid caveolin dissociation and calmodulin 
association. J. Biol. Chem., 1998, 273, 34724-34729. 
[93]  Boo, Y.C.; Hwang, J.; Sykes, M.; Michell, B.J.; Kemp, B.E.; Lum, 
H.; Jo, H. Shear stress stimulates phosphorylation of eNOS at 
Ser(635) by a protein kinase A-dependent mechanism. Am. J . 
Physiol. Heart Circ. Physiol., 2002, 283, H1819-1828. 
[94]  Boo, Y.C.; Sorescu, G.; Boyd, N.; Shiojima, I.; Walsh, K.; Du, J.; 
Jo, H. Shear stress stimulates phosphorylation of endothelial nitric-
oxide synthase at Ser1179 by Akt-independent mechanisms: role of 
protein kinase A. J. Biol. Chem., 2002, 277, 3388-3396. 
[95]  Noris, M.; Morigi, M.; Donadelli, R.; Aiello, S.; Foppolo, M.; 
Todeschini, M.; Orisio, S.; Remuzzi, G.; Remuzzi, A. Nitric oxide 
synthesis by cultured endothelial cells is modulated by flow 
conditions. Circ. Res., 1995, 76, 536-543. 
[96]  Sessa, W.C.; Pritchard, K.; Seyedi, N.; Wang, J.; Hintze, T. H. 
Chronic exercise in dogs increases coronary vascular nitric oxide 
production and endothelial cell nitric oxide synthase gene 
expression. Circ. Res., 1994, 74, 349-353. 
[97]  Varin, R.; Mulder, P.; Richard, V.; Tamion, F.; Devaux, C.; Henry, 
J.P.; Lallemand, F.; Lerebours, G.; Thuillez, C. Exercise improves 
flow-mediated vasodilatation of skeletal muscle arteries in rats with 
chronic heart failure. Role of nitric oxide, prostanoids, and oxidant 
stress. Circulation, 1999, 99, 2951-2957. 
[98]  Widder, J.D.; Chen, W.; Li, L.; Dikalov, S.; Thony, B.; 
Hatakeyama, K.; Harrison, D. G. Regulation of tetrahydrobiopterin 
biosynthesis by shear stress. Circ. Res., 2007, 101, 830-838. 
[99]  Ennezat, P.V.; Malendowicz, S.L.; Testa, M.; Colombo, P.C.; 
Cohen-Solal, A.; Evans, T.; LeJemtel, T.H. Physical training in 
patients with chronic heart failure enhances the expression of genes 
encoding antioxidative enzymes. J. Am. Coll. Cardiol., 2001, 38, 
194-198. 
[100]  Linke, A.; Adams, V.; Schulze, P.C.; Erbs, S.; Gielen, S.; Fiehn, E.; 
Mobius-Winkler, S.; Schubert, A.; Schuler, G.; Hambrecht, R. 
Antioxidative effects of exercise training in patients with chronic 
heart failure: increase in radical scavenger enzyme activity in 
skeletal muscle. Circulation, 2005, 111, 1763-1770. 
[101]  Parnell, M. M.; Holst, D. P.; Kaye, D. M., Augmentation of 
endothelial function following exercise training is associated with 
increased L-arginine transport in human heart failure. Clin. Sci., 
2005, 109, 523-530. 
[102]  Wang, J.S.; Chow, S.E. Effects of exercise training and detraining 
on oxidized low-density lipoprotein-potentiated platelet function in 
men. Arch. Phys. Med. Rehabil., 2004, 85, 1531-1537. 
[103]  Anker, S.D.; Ponikowski, P.P.; Clark, A.L.; Leyva, F.; Rauchhaus, 
M.; Kemp, M.; Teixeira, M.M.; Hellewell, P.G.; Hooper, J.; Poole-
Wilson, P.A.; Coats, A.J. Cytokines and neurohormones relating to 
body composition alterations in the wasting syndrome of chronic 
heart failure. Eur. Heart J., 1999, 20, 683-693. 
[104]  Oliff, A.; Defeo-Jones, D.; Boyer, M.; Martinez, D.; Kiefer, D.; 
Vuocolo, G.; Wolfe, A.; Socher, S.H. Tumors secreting human 
TNF/cachectin induce cachexia in mice. Cell, 1987, 50, 555-563. 
[105]  Adams, V.; Spate, U.; Krankel, N.; Schulze, P.C.; Linke, A.; 
Schuler, G.; Hambrecht, R. Nuclear factor-kappa B activation in 
skeletal muscle of patients with chronic heart failure: correlation 
with the expression of inducible nitric oxide synthase. Eur. J . 
Cardiovasc. Prev. Rehabil., 2003, 10, 273-277. 
[106]  De Sousa, E.; Veksler, V.; Bigard, X.; Mateo, P.; Ventura-Clapier, 
R. Heart failure affects mitochondrial but not myofibrillar intrinsic 
properties of skeletal muscle. Circulation, 2000, 102, 1847-1853. 
[107]  Fogli, S.; Nieri, P.; Breschi, M.C. The role of nitric oxide in 
anthracycline toxicity and prospects for pharmacologic prevention 
of cardiac damage. FASEB J., 2004, 18, 664-675. 
[108]  Gielen, S.; Adams, V.; Mobius-Winkler, S.; Linke, A.; Erbs, S.; 
Yu, J.; Kempf, W.; Schubert, A.; Schuler, G.; Hambrecht, R. Anti-
inflammatory effects of exercise training in the skeletal muscle of 
patients with chronic heart failure. J. Am. Coll. Cardiol., 2003, 42, 
861-868. 
[109]  Gielen, S.; Adams, V.; Linke, A.; Erbs, S.; Mobius-Winkler, S.; 
Schubert, A.; Schuler, G.; Hambrecht, R. Exercise training in 
chronic heart failure: correlation between reduced local 
inflammation and improved oxidative capacity in the skeletal 
muscle. Eur. J. Cardiovasc. Prev. Rehabil., 2005, 12, 393-400. 
[110]  Adamopoulos, S.; Parissis, J.; Karatzas, D.; Kroupis, C.; 
Georgiadis, M.; Karavolias, G.; Paraskevaidis, J.; Koniavitou, K.; 
Coats, A.J.; Kremastinos, D.T. Physical training modulates 
proinflammatory cytokines and the soluble Fas/soluble Fas ligand 
system in patients with chronic heart failure. J. Am. Coll. Cardiol., 
2002, 39, 653-663. 
[111]  Conraads, V.M.; Beckers, P.; Bosmans, J.; De Clerck, L.S.; 
Stevens, W.J.; Vrints, C.J.; Brutsaert, D.L. Combined 
endurance/resistance training reduces plasma TNF-alpha receptor 
levels in patients with chronic heart failure and coronary artery 
disease. Eur. Heart J., 2002, 23, 1854-1860. 
[112]  Niebauer, J.; Clark, A.L.; Webb-Peploe, K.M.; Coats, A.J. Exercise 
training in chronic heart failure: effects on pro-inflammatory 
markers. Eur. J. Heart Fail., 2005, 7, 189-193. 
[113]  Katz, S.D.; Rao, R.; Berman, J.W.; Schwarz, M.; Demopoulos, L.; 
Bijou, R.; LeJemtel, T.H. Pathophysiological correlates of 
increased serum tumor necrosis factor in patients with congestive 
heart failure. Relation to nitric oxide-dependent vasodilation in the 
forearm circulation. Circulation, 1994, 90, 12-16. 
[114]  Testa, M.; Yeh, M.; Lee, P.; Fanelli, R.; Loperfido, F.; Berman, 
J.W.; LeJemtel, T.H. Circulating levels of cytokines and their 
endogenous modulators in patients with mild to severe congestive Heart Failure, Nitric Oxide and Exercise  The Open Biochemistry Journal, 2009, Volume 3    65 
heart failure due to coronary artery disease or hypertension. J. Am. 
Coll. Cardiol., 1996, 28, 964-971. 
[115]  Munger, M.A.; Johnson, B.; Amber, I.J.; Callahan, K.S.; Gilbert, 
E.M. Circulating concentrations of proinflammatory cytokines in 
mild or moderate heart failure secondary to ischemic or idiopathic 
dilated cardiomyopathy. Am. J. Cardiol., 1996, 77, 723-727. 
[116]  Dunlay, S.M.; Weston, S.A.; Redfield, M.M.; Killian, J.M.; Roger, 
V.L. Tumor necrosis factor-alpha and mortality in heart failure: a 
community study. Circulation, 2008, 118, 625-631. 
[117]  Parish, R.C.; Evans, J.D. Inflammation in chronic heart failure. 
Ann. Pharmacother. 2008, 42, 1002-1016. 
[118]  Torre-Amione, G.; Kapadia, S.; Benedict, C.; Oral, H.; Young, J. 
B.; Mann, D. L. Proinflammatory cytokine levels in patients with 
depressed left ventricular ejection fraction: a report from the 
Studies of Left Ventricular Dysfunction (SOLVD). J. Am. Coll. 
Cardiol., 1996, 27, 1201-1206. 
[119]  Lommi, J.; Pulkki, K.; Koskinen, P.; Naveri, H.; Leinonen, H.; 
Harkonen, M.; Kupari, M. Haemodynamic, neuroendocrine and 
metabolic correlates of circulating cytokine concentrations in 
congestive heart failure. Eur. Heart J., 1997, 18, 1620-1625. 
[120]  Abdallah, A.N.; Billes, M.A.; Attia, Y.; Doutremepuich, C.; 
Cassaigne, A.; Iron, A. Evaluation of plasma levels of tumour 
necrosis factor alpha and interleukin-6 as rejection markers in a 
cohort of 142 heart-grafted patients followed by endomyocardial 
biopsy. Eur. Heart J. 1997, 18, 1024-1029. 
[121]  Mehra, M.R.; Maisel, A. B-type natriuretic peptide in heart failure: 
diagnostic, prognostic, and therapeutic use. Crit. Pathw. Cardiol., 
2005, 4, 10-20. 
[122]  Nian, M.; Lee, P.; Khaper, N.; Liu, P. Inflammatory cytokines and 
postmyocardial infarction remodeling. Circ. Res., 2004, 94, 1543-
1553. 
[123]  Haudek, S. B.; Taffet, G. E.; Schneider, M. D.; Mann, D. L., TNF 
provokes cardiomyocyte apoptosis and cardiac remodeling through 
activation of multiple cell death pathways. J. Clin. Invest., 2007, 
117, 2692-2701. 
 
 
 
Received: July 02, 2009  Revised: July 24, 2009  Accepted: August 20, 2009 
 
© Mendes-Ribeiro et al.; Licensee Bentham Open. 
 
This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License 
(http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the 
work is properly cited. 
 